Clinical evaluation of nuclear matrix protein 22 in urine for bladder cancer / 中华泌尿外科杂志

ABSTRACT

Objective To determine the clinical efficac y of nuclear matrix protein 22(NMP22) as a novel urine marker for bladder cance r. Methods Urine NMP22 values were determined for 18 bla dder cancer patients and 20 urological benign disease patients by an enzyme-lin ked immunosorbent assay (ELISA). Results Median NMP22 va lue for the bladder cancers was 44.3 IU/L vs 5.8 IU/L for urological benign dise ases. The urinary NMP22 values in the bladder cancer group were significantly hi gher than those in the benign condition group (P